Dicerna Pharmaceuticals (DRNA) Scheduled to Post Earnings on Wednesday

Dicerna Pharmaceuticals (NASDAQ:DRNA) is scheduled to be releasing its earnings data after the market closes on Wednesday, August 8th. Analysts expect Dicerna Pharmaceuticals to post earnings of ($0.42) per share for the quarter.

Dicerna Pharmaceuticals (NASDAQ:DRNA) last released its quarterly earnings data on Monday, May 14th. The biopharmaceutical company reported ($0.30) EPS for the quarter, topping analysts’ consensus estimates of ($0.87) by $0.57. The firm had revenue of $1.55 million during the quarter, compared to the consensus estimate of $1.75 million. Dicerna Pharmaceuticals had a negative net margin of 1,665.11% and a negative return on equity of 123.72%. On average, analysts expect Dicerna Pharmaceuticals to post $-1 EPS for the current fiscal year and $-1 EPS for the next fiscal year.

Dicerna Pharmaceuticals stock opened at $13.10 on Monday. The firm has a market capitalization of $691.97 million, a price-to-earnings ratio of -3.58 and a beta of 2.33. Dicerna Pharmaceuticals has a 12 month low of $2.69 and a 12 month high of $15.80.

In related news, insider James B. Weissman sold 10,000 shares of the firm’s stock in a transaction on Wednesday, May 9th. The shares were sold at an average price of $15.00, for a total transaction of $150,000.00. Following the completion of the transaction, the insider now owns 19,800 shares of the company’s stock, valued at $297,000. The sale was disclosed in a filing with the SEC, which is available at the SEC website. Company insiders own 19.85% of the company’s stock.

DRNA has been the subject of a number of research analyst reports. BidaskClub cut shares of Dicerna Pharmaceuticals from a “buy” rating to a “hold” rating in a report on Friday, June 8th. Cowen reaffirmed a “buy” rating on shares of Dicerna Pharmaceuticals in a report on Tuesday, April 24th. ValuEngine raised shares of Dicerna Pharmaceuticals from a “hold” rating to a “buy” rating in a report on Thursday, April 12th. Evercore ISI reaffirmed an “outperform” rating and issued a $17.00 price target (up previously from $14.00) on shares of Dicerna Pharmaceuticals in a report on Friday, April 20th. Finally, HC Wainwright reaffirmed a “hold” rating and issued a $14.00 price target on shares of Dicerna Pharmaceuticals in a report on Tuesday, May 15th. One equities research analyst has rated the stock with a sell rating, four have given a hold rating and five have assigned a buy rating to the company. Dicerna Pharmaceuticals currently has an average rating of “Hold” and an average price target of $12.88.

Dicerna Pharmaceuticals Company Profile

Dicerna Pharmaceuticals, Inc, a biopharmaceutical company, focuses on the discovery and development of pharmaceuticals for the treatment of rare, viral infectious, chronic liver, and cardiovascular diseases. Its development programs include DCR-PHXC for the treatment of primary hyperoxaluria; DCR-HBVS for the treatment of chronic hepatitis B virus infection; and DCR-PCSK9 to treat hypercholesterolemia.

Further Reading: How to Invest in Growth Stocks

Earnings History for Dicerna Pharmaceuticals (NASDAQ:DRNA)

Receive News & Ratings for Dicerna Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Dicerna Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.


Leave a Reply

share news on Facebook
tweet this investment news
share on linkedin
share on StockTwits
share on Google Plus
share on reddit